Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: Comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin

Cancer Research

Volumn 66, Issue 2, 2006, Pages 989-998

  Lockley, Michelle ^a   Fernandez, Mario ^a   Wang, Yaohe ^a   Li, N Fiona ^a   Conroy, Susan ^b   Lemoine, Nicholas ^a   McNeish, Iain ^a,c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Elan Drug Delivery Ltd   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

E1A PROTEIN; ICODEXTRIN; RETINOBLASTOMA PROTEIN; VIRUS PROTEIN;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL IMMORTALIZATION; COMPARATIVE STUDY; CONTROLLED STUDY; DELETION MUTANT; ENHANCER REGION; EPITHELIUM CELL; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TUMOR XENOGRAFT; VIRUS EXPRESSION; VIRUS REPLICATION; WILD TYPE;

ADENOVIRIDAE; ANIMALS; CARCINOMA; CELL PROLIFERATION; FEMALE; FRAMESHIFT MUTATION; GLUCANS; GLUCOSE; HUMANS; IMMUNOCOMPETENCE; INFUSIONS, PARENTERAL; LIVER; LUCIFERASES; LUMINESCENT MEASUREMENTS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; VIRUS REPLICATION;

EID: 31544471784     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2691     Document Type: Article

References (31)

1. Bray F, Loos AH, Tognazzo S, La Vecchia C. Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Int J Cancer 2005;113:977-90.
2. Ozols RF, Bundy BN, Greer BE, et al. Phase III Trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200.
3. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335: 1950-5.
4. Zeimet AG, Marth C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol 2003;4:415-22.
5. Heise C, Sampson-Johannes A, Williams A, McCormick F, von Hoff D, Kirn D. ONYX-015, an E1B gene attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3: 639-44.
6. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2:103-12.
7. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 2001; 8:89-98.
8. Vasey PA, Shulman LN, Campos S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002;20:1562-9.
9. O'Shea C, Johnson L, Bagus B, et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004;6:611-23.
10. D'Andrilli G, Kumar C, Scambia G, Giordano A. Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies. Clin Cancer Res 2004;10: 8132-41.
11. Heise C, Hermiston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000;6:1134-9.
12. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000;19:2-12.
13. Hosie K, Gilbert JA, Kerr D, Brown CB, Peers EM. Fluid dynamics in man of an intraperitoneal drug delivery solution: 4% icodextrin. Drug Deliv 2001;8:9-12.
14. Engler H, Machemer TR, Schluep T, et al. Development of a formulation that enhances gene expression and efficacy following intraperitoneal administration in rabbits and mice. Mol Ther 2003;7:558-64.
15. Li NF, Gayther SA, Balkwill F. A cellular model for studying human ovarian surface epithelium carcinogensis. Proc Am Assoc Cancer Res 2005;46:LB-176.
16. Li NF, Wilbanks G, Balkwill F, Jacobs IJ, Dafou D, Gayther SA. A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro. Lab Invest 2004;84:923-31.
17. McNeish IA, Tenev T, Bell S, Marani M, Vassaux G, Lemoine N. Herpes simplex virus thymidine kinase/ ganciclovir-induced cell death is enhanced by coexpression of caspase-3 in ovarian carcinoma cells. Cancer Gene Ther 2001;8:308-19.
18. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
19. Tubiana M, Malaise E. Growth rate and cells kinetics in human tumours: some prognostic and therapeutic implications. In: Symington T, Carter R, editors. Scientific foundations of oncology. London: Heinnemann; 1976. p. 126-36.
20. Bauerschmitz GJ, Lam JT, Kanerva A, et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 2002;62:1266-70.
21. Kanerva A, Zinn KR, Chaudhuri TR, et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003; 8:449-58.
22. Weedon S, Green N, McNeish I, et al. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E coli nitro-reductase. Int J Cancer 2000;86:848-54.
23. Steinwaerder DS, Carlson CA, Lieber A. DNA replication of first-generation adenovirus vectors in tumor cells. Hum Gene Ther 2000;11:1933-48.
24. O'Connor RJ, Hearing P. The E4-6/7 protein functionally compensates for the loss of E1A expression in adenovirus infection. J Virol 2000;74:5819-24.
25. Shayakhmetov DM, Li Z-Y, Ni S, Lieber A. Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol 2004;78:5368-81.
26. Shayakhmetov DM, Gaggar A, Ni S, Li Z-Y, Lieber A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 2005;79:7478-91.
27. Engler H, Machemer T, Philopena J, et al. Acute hepatotoxicity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a and induction of TNF-α. Virology 2004;328:52-61.
28. Heise C, Ganly I, Kim YT, Sampson-Johannes A, Brown R, Kim D. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Gene Ther 2000;7:1925-9.
29. Raki M, Kanerva A, Ristimaki A, et al. Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther 2005;12:1298-05.
30. Engler H, Machemer T, Philopena J, et al. Acute hepatotoxicity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a and induction of TNF-[α]. Virology 2004;328:52-61.
31. Kanerva A, Zinn KR, Peng KW, et al. Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. Gene Ther 2005;12:87-94.